Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AstraZeneca
Biotech
AstraZeneca drops GOLDILOX and the porcupine in R&D update
The drugmaker axed a cardiovascular disease prospect while stopping work on early-stage assets bought in from Ionis and Redx Pharma.
Nick Paul Taylor
Apr 25, 2024 3:24am
Biopharma M&A more than doubled in Q1 compared to a year ago
Apr 18, 2024 9:46am
AACR: AstraZeneca PARP inhibitor gives 'bang for your buck'
Apr 9, 2024 5:00am
AACR: Dogs, smoothies and AstraZeneca's nap-worthy carpet
Apr 8, 2024 5:00am
AstraZeneca melds with Fusion in $2B radiopharma buyout
Mar 19, 2024 5:52am
Top 10 pharma R&D budgets in 2023
Mar 18, 2024 5:00am